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Abstract
Background: There is an urgent unmet clinical need for the identification of novel therapeutics for the treatment
of COVID-19. A number of COVID-19 late phase trial platforms have been developed to investigate (often
repurposed) drugs both in the UK and globally (e.g. RECOVERY led by the University of Oxford and SOLIDARITY led
by WHO). There is a pressing need to investigate novel candidates within early phase trial platforms, from which
promising candidates can feed into established later phase platforms. AGILE grew from a UK-wide collaboration to
undertake early stage clinical evaluation of candidates for SARS-CoV-2 infection to accelerate national and global
healthcare interventions.
Methods/design: AGILE is a seamless phase I/IIa platform study to establish the optimum dose, determine the
activity and safety of each candidate and recommend whether it should be evaluated further. Each candidate is
evaluated in its own trial, either as an open label single arm healthy volunteer study or in patients, randomising
between candidate and control usually in a 2:1 allocation in favour of the candidate. Each dose is assessed
sequentially for safety usually in cohorts of 6 patients. Once a phase II dose has been identified, efficacy is assessed
by seamlessly expanding into a larger cohort. AGILE is completely flexible in that the core design in the master
protocol can be adapted for each candidate based on prior knowledge of the candidate (i.e. population, primary
endpoint and sample size can be amended). This information is detailed in each candidate specific trial protocol of
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the master protocol.
Discussion: Few approved treatments for COVID-19 are available such as dexamethasone, remdesivir and
tocilizumab in hospitalised patients. The AGILE platform aims to rapidly identify new efficacious and safe treatments
to help end the current global COVID-19 pandemic. We currently have three candidate specific trials within this
platform study that are open to recruitment.
Trial registration: EudraCT Number: 2020-001860-27 14 March 2020
ClinicalTrials.gov Identifier: NCT04746183 19 February 2021
ISRCTN reference: 27106947
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Background
In 2019, a novel coronavirus disease (COVID-19)
emerged in Wuhan, China, which is caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
[1]. Many patients do not progress to severe disease, but
as COVID-19 spread across the world, vast numbers of
patients have been hospitalised with respiratory failure, a
significant proportion of whom have become critically
unwell and died [2–4]. The progression from initial
symptoms, most commonly fever, fatigue and cough, to
respiratory failure requiring oxygen support or mechan-
ical ventilation occurs several days after the onset of
symptoms [2]. While treatment options such as dexa-
methasone, remdesivir and tocilizumab are now available
for certain hospitalised patients with severe disease,
these are repurposed medicines [5, 6]. AGILE is unique
as it provides a platform for assessing novel therapeutic
agents. There is also a distinct lack of available treat-
ment options for the early phase of infection which may
help prevent progression to severe disease [7].
Given the rapid and global spread of COVID-19 and
the emergence of new variants in the UK, South Africa,
India and Brazil, a robust but rapid assessment of poten-
tial treatments is needed [8]. The AGILE platform aims
to identify new candidates with promising evidence of
efficacy that can be further evaluated in subsequent lar-
ger phase IIb/III trials. Having one master protocol en-
sures different candidates are evaluated in the same
consistent manner and enables more efficient introduc-
tion of new trials for new candidates.
Methods/design
Objectives
Phase I—To determine the optimal dose of each candi-
date (or combination of candidates) entered into the
platform. Phase II—To determine the efficacy and safety
of each candidate entered into the platform, compared
to the current Standard of Care (SoC), and recommend
whether it should be evaluated further in later phase II
and III platforms.
Trial design
AGILE is a multicentre, multi-candidate, multi-dose,
multi-stage, randomised phase I/IIa Bayesian adaptive
platform trial to determine the safety and efficacy of
multiple candidate agents for the treatment of COVID-
19. The multi-candidate design allows many candidates
to be tested simultaneously (while potentially sharing
control group data, provided they are at least contem-
poraneously recruited), in order to increase efficiency
compared to multiple single-candidate studies. The
multi-dose feature allows progression beyond the li-
censed dose dependent on adequate safety and tolerabil-
ity data and promising efficacy. The multi-stage feature
allows for pre-specified analyses that can be used to de-
termine dropping of ineffective doses or candidates or
recommending doses or candidates for further phase II/
III testing, further increasing efficiency of the study. The
adaptive platform design allows for the removal of un-
promising candidates, promising candidates to be rec-
ommended for further testing in external phase II/III
studies, and the addition of new potential treatments to
be added during the trial. Candidates will be added into
the AGILE platform study via candidate specific trial
(CST) protocols to the master protocol.
Participants
Patient populations can vary between CSTs, but the
main eligibility criteria include adult patients (≥ 18 years)
who have laboratory-confirmed infection with SARS-
CoV-2. We will include both severe and mild-moderate
patients as well as healthy volunteers defined as follows:
group A (severe disease)—patients with WHO Clinical
Progression Scale [9] of grades 5 (hospitalised, oxygen
by mask or nasal prongs), 6 (hospitalised, non-invasive
ventilation or high flow oxygen), 7 [hospitalised, intub-
ation and mechanical ventilation, arterial oxygen partial
pressure (PaO2)/fractional inspired oxygen (FiO2) ≥ 150
or peripheral capillary oxygen saturation (SpO2)/FiO2 ≥
200], 8 [hospitalised mechanical ventilation PaO2/FiO2 <
150 (SpO2/FiO2 < 200) or vasopressors] or 9 (hospita-
lised, mechanical ventilation pO2/FiO2 < 150 and
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vasopressors, dialysis or ECMO). Group B (mild-moder-
ate disease)—ambulant or hospitalised patients with
SpO2 > 94% room air. If any CSTs include participants
from the community setting, the CST protocol will clar-
ify whether patients with suspected SARS-CoV-2 infec-
tion (in addition to laboratory-confirmed infection) are
also eligible. Group C (healthy volunteers)—to be de-
fined in each CST protocol. Participants are currently
being recruited from the UK, but we intend to open up
recruitment at international sites later in 2021.
Intervention and comparator
The comparator is the current SoC, and in some CSTs,
placebo is added to the current SoC. Candidates that pre-
vent uncontrolled cytokine release, prevention of viral rep-
lication, and other anti-viral treatment strategies are at
various stages of development for inclusion into AGILE.
Other CSTs will be added over time. There is not a set
limit on the number of CSTs we can include within the
AGILE master protocol, and we will upload each CST into
this publication as each opens to recruitment.
Main outcomes
Phase I—Dose limiting toxicities using Common Ter-
minology Criteria for Adverse Events (CTCAE) Version
5 Grade ≥ 3 adverse events. Phase II—Agreed on a CST
basis depending on mechanism of action of the candi-
date and patient population, but may include time to
clinical improvement of at least 2 points on the WHO
Clinical Progression Scale [measured up to 29 days from
randomisation], progression of disease (SpO2 < 92%) or
hospitalisation or death, or change in time-weighted
viral load [measured up to 29 days from randomisation].
Randomisation and blinding
Each candidate will be evaluated in its own CST, either
as an open label single arm healthy volunteer study or in
patients, randomising between candidate and control.
Randomisation varies with each CST, but the default is
2:1 allocation in favour of the candidate to maximise
early safety data. Each dose will be assessed sequentially
for safety in cohorts of patients; the default size is 6 pa-
tients per cohort. Once a phase II dose has been identi-
fied, we will assess efficacy by seamlessly expanding into
a larger cohort.
Numbers to be randomised (sample size)
Sample size varies between CSTs. Simulations have
shown that around 16 participants are necessary to de-
termine futility or promise of a candidate at a given dose
(in efficacy evaluation alone) and between 32 and 40
participants are required across the dose-finding and ef-
ficacy evaluation when capping the maximum number
of participants contributing to the evaluation of a
treatment at 40. Each CST protocol will give details on
the sample size needed for that candidate and a justifica-
tion for any CST needing more than 40 participants.
Full protocol
The full AGILE master protocol is attached as an add-
itional file, accessible from the Trials website www.
agiletrial.net (Additional file 1). In the interest of exped-
iting dissemination of this material, the familiar format-
ting has been eliminated; this addendum is an update to
the original letter and serves as a summary of the key el-
ements of the full master protocol and trial status of ac-
tive CSTs.
Discussion
AGILE is the first and only phase I/IIa national clinical
trial platform in the UK to determine the safety and effi-
cacy of promising candidate agents for COVID-19. It
bridges the gap between preclinical development and
later phase trials, so that potential new treatments can
pass through the phases of drug development in a rapid
and safe manner. An independent COVID-19 Therapeu-
tics Advisory Panel (UK-CTAP) will evaluate and priori-
tise candidate agents for inclusion in the study. The
design of AGILE allows for the assessment of multiple
candidates at different doses, with the ability to add can-
didates as they are identified or drop them as their
evaluation is completed. Promising candidates will move
to an external trial for further evaluation in the phase II/
III setting. AGILE is completely flexible and each CST
design is catered to the requirement of the candidate
whereby population, primary endpoint and sample size
can be amended. AGILE has full regulatory approval [by
the UK MHRA, ethics and HRA and the WHO Research
Ethics Review Committee (ERC)] and has three CSTs
currently open to recruitment with a number of others
at various stages of development. AGILE has the poten-
tial to rewrite the treatment landscape for COVID-19
and shape our response to future global pandemics.
Trial status
AGILE master protocol
The AGILE master protocol Version 9 (17 February
2021) has full regulatory approval and utilises several
digital technology solutions, including Medidata’s Rave
Electronic Data Capture (EDC), Randomization and
Trial Supply Management (RTSM) for randomisation
and drug distribution, patient eConsent on iPads and
electronic Clinical Outcome Assessment (eCOA) to col-
lect patient reported outcome measures via an App on
the participants smart phones.
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CST-2: a randomised, multicentre, seamless, adaptive,
phase I/II platform study to determine the optimal dose,
safety and efficacy of Molnupiravir (EIDD-2801) for the
treatment of COVID-19
CST-2 has full regulatory approval, has completed phase
I and has successfully determined a dose for phase II
evaluation. Phase II recruitment is ongoing following a
planned interim analysis by an Independent Data Moni-
toring Committee. Molnupiravir is being evaluated in
adult ambulant patients with laboratory confirmed
COVID-19, who are within 5 days of symptom onset in
the UK. Molnupiravir (EIDD-2801) is the 5′-isopropyl
ester prodrug of the broadly active, direct-acting anti-
viral ribonucleoside analogue EIDD-1931. Molnupiravir
is being developed for the treatment of infections caused
by RNA viruses, specifically for COVID-19 and other
coronavirus infections, influenza and Venezuelan equine
encephalitis virus [10, 11].
CST-3A: a multicentre, adaptive, phase I trial to determine
the optimal dose, safety and efficacy of nitazoxanide for
the treatment of COVID-19
CST-3A has full regulatory approval and has recently
completed recruitment. Nitazoxanide is being evaluated
in healthy adults in the UK. Nitazoxanide is a thiazolide
FDA-approved antiparasitic medicine used for the treat-
ment of cryptosporidiosis and giardiasis diarrhoea but
has been studied previously for viruses including influ-
enza [12]. However, preclinical candidate evaluation by
AGILE investigators using data from in vitro antiviral
activity and historical human pharmacokinetic studies
strongly suggests that doses higher than those approved
will be required for durable antiviral activity in SARS-
CoV-2 infection [13, 14]. N.B. Once CST-3A has com-
pleted in the UK, it is planned that a CST-3B phase Ib/II
trial will open in South Africa and Uganda in adult am-
bulant patients with laboratory-confirmed COVID-19.
CST-5: a randomised, multicentre, seamless, adaptive,
phase I/II platform study to determine the phase II dose
of VIR-7832, and evaluate the safety and efficacy of VIR-
7831 and VIR-7832 for the treatment of COVID-19
CST-5 has full regulatory approval and phase I is cur-
rently recruiting. VIR-7832 and VIR-7831 are being eval-
uated in adult ambulant patients with laboratory-
confirmed COVID-19, who are within 5 days of symp-
tom onset in the UK. VIR-7832 and VIR-7831 are both
human monoclonal antibodies that neutralise COVID-
19 by targeting the receptor-binding domain of the
SARS-CoV-2 Spike (S) glycoprotein [15]. The binding of
this domain inhibits the entry of the SARS-CoV-2 virus
into the host cell. VIR-7832 includes the “XX2” modifi-
cation in the fragment crystallisable domain. The XX2
modification is designed to enhance effector functions,
abrogate C1q binding and elicit enhanced T cell and
antibody responses [16].
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